Literature DB >> 2946602

RNA structural elements for expression in Escherichia coli. Alpha 1-antitrypsin synthesis using translation control elements based on the cII ribosome-binding site of phage lambda.

L H Tessier, S Jallat, M Sauvageot, R G Crystal, M Courtney.   

Abstract

Analysis of a series of lambda cII::alpha 1-antitrypsin (alpha 1AT) gene fusions of different sizes showed that increased alpha 1AT expression correlated with the stabilisation of a particular computer-predicted RNA secondary structure. Moreover, significant synthesis of unfused alpha 1AT was achieved by reconstruction of this conformation to permit interaction between the upstream region of the ribosome-binding site and the first part of the alpha 1AT coding sequence. This high-level expression was dependent upon certain silent point mutations in the coding sequence, indicating that RNA primary and secondary structure determinants can operate in concert to dictate the efficiency of protein synthesis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2946602     DOI: 10.1016/0014-5793(86)81014-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  4 in total

1.  Construction and use of lambda PL promoter vectors for direct cloning and high level expression of PCR amplified DNA coding sequences.

Authors:  X Cheng; T A Patterson
Journal:  Nucleic Acids Res       Date:  1992-09-11       Impact factor: 16.971

2.  Development of stable, genetically well-defined conditionally viable Escherichia coli strains.

Authors:  E Degryse
Journal:  Mol Gen Genet       Date:  1991-05

3.  The initiation of translation in E. coli: apparent base pairing between the 16srRNA and downstream sequences of the mRNA.

Authors:  M L Sprengart; H P Fatscher; E Fuchs
Journal:  Nucleic Acids Res       Date:  1990-04-11       Impact factor: 16.971

Review 4.  Engineering the serpin α1 -antitrypsin: A diversity of goals and techniques.

Authors:  Benjamin M Scott; William P Sheffield
Journal:  Protein Sci       Date:  2019-12-09       Impact factor: 6.725

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.